Cargando…

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients

SIMPLE SUMMARY: In this study we have isolated and analyzed atypical cells found in the blood of metastatic breast cancer patients using a micro-filtration technic. This technic, being very easy to implement, was also extremely useful for studying circulating tumors cells’ (CTCs) heterogeneity in ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopresti, Alexia, Acquaviva, Claire, Boudin, Laurys, Finetti, Pascal, Garnier, Séverine, Aulas, Anaïs, Liberatoscioli, Maria Lucia, Cabaud, Olivier, Guille, Arnaud, de Nonneville, Alexandre, Da Costa, Quentin, Denicolai, Emilie, Pakradouni, Jihane, Goncalves, Anthony, Birnbaum, Daniel, Bertucci, François, Mamessier, Emilie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869799/ https://www.ncbi.nlm.nih.gov/pubmed/35205679 http://dx.doi.org/10.3390/cancers14040932

Ejemplares similares

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
por: Aulas, Anaïs, et al.
Publicado: (2022)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?
por: Aulas, Anaïs, et al.
Publicado: (2020)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial
por: Sabatier, Renaud, et al.
Publicado: (2022)

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
por: Billon, Emilien, et al.
Publicado: (2022)

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study
por: Sabatier, Renaud, et al.
Publicado: (2022)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Validation and comparison of the molecular classifications of pancreatic carcinomas
por: Birnbaum, David J., et al.
Publicado: (2017)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2017)

A machine learning-based algorithm to eliminate breast and axillary surgery in patients with breast cancer and pathological complete response after neoadjuvant chemotherapy
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
por: Bertucci, François, et al.
Publicado: (2021)

Comparative genomic analysis of primary tumors and metastases in breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases
por: Tyran, Marguerite, et al.
Publicado: (2019)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
por: Bertucci, François, et al.
Publicado: (2018)

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
por: Mari, Roxane, et al.
Publicado: (2019)

Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2011)

Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
por: Nigon, Elsa, et al.
Publicado: (2023)

Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy
por: Neron, Mathias, et al.
Publicado: (2022)

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study
por: Gonçalves, Anthony, et al.
Publicado: (2016)

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines
por: Udu-Ituma, Sandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_95d1ljeq97qc346h6msugr1n32